|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...2930313233343536373839...110111» |
- New trial: Comparing Pregnancy Outcomes in Good Prognosis Patients Between Fresh and 'Freeze-All' Single Blastocyst Transfers (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=118, Recruiting, Sponsor: Mount Sinai Hospital, Canada
- New P3 trial: Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies. (clinicaltrials.gov) - Mar 18, 2016
P3, N=0, Withdrawn, Sponsor: Ache Laboratorios Farmaceuticos S.A.
- Trial completion, Preclinical, Enrollment change, Trial primary completion date: Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=16, Completed, Sponsor: Duke University
Active, not recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Jan 2016 --> Aug 2015
- New trial: Automatic Volume Calculations During Three-dimensional Sonohysterography. (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=100, Recruiting, Sponsor: Ludwin & Ludwin Gynecology, Private Medical Center
- Trial completion, Trial primary completion date: MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study (clinicaltrials.gov) - Mar 16, 2016
P=N/A, N=10, Completed, Sponsor: Maastricht University Medical Center
Active, not recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Jan 2016 --> Aug 2015 Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Mar 2016
- | New P2 trial: Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Mar 15, 2016
P2, N=120, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Trial completion: Can Text Reminders Improve Uptake of Cervical Screening? (clinicaltrials.gov) - Mar 15, 2016
P=N/A, N=14597, Completed, Sponsor: Sarah Huf
Recruiting --> Completed | Trial primary completion date: Oct 2015 --> Mar 2016 Enrolling by invitation --> Completed
- New trial: ROABTIPWSIUA: Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions (clinicaltrials.gov) - Mar 15, 2016
P=N/A, N=82, Completed, Sponsor: Yuqing Chen
- New trial: Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer (clinicaltrials.gov) - Mar 15, 2016
P=N/A, N=10, Recruiting, Sponsor: Sanjiv Sam Gambhir
- cefixime / Generic mfg., azithromycin / Generic mfg.
New P1 trial: Cefixime / Azithromycin pK Study (clinicaltrials.gov) - Mar 15, 2016
P1, N=8, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- veliparib (ABT-888) / AbbVie
Enrollment closed, Combination therapy: Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer (clinicaltrials.gov) - Mar 15, 2016
P1, N=12, Active, not recruiting, Sponsor: AbbVie
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- Trial primary completion date, HEOR, Surgery, Patient reported outcomes: Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=120, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Mar 2017
- Trial completion, Phase classification, Enrollment change: The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding (clinicaltrials.gov) - Mar 14, 2016
P1/2, N=61, Completed, Sponsor: Ain Shams Maternity Hospital
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Completed | Phase classification: P3 --> P1/2 | N=50 --> 61
- p53MVA - Tara I / O
Trial primary completion date, Combination therapy: p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (clinicaltrials.gov) - Mar 14, 2016
P1, N=9, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Completed | Phase classification: P3 --> P1/2 | N=50 --> 61 Trial primary completion date: Jun 2016 --> Sep 2016
- || Enrollment change, BRCA Biomarker, IO biomarker: ENGAGE: Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=550, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Jun 2016 --> Sep 2016 N=400 --> 550
- Trial completion, Trial primary completion date: LACRING01: Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis (clinicaltrials.gov) - Mar 14, 2016
P1, N=6, Completed, Sponsor: University Ghent
N=400 --> 550 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jan 2015
- clomifene citrate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: DNAFRAG: The Predictive Value of the Sperm Chromatin Dispersion Test, Halosperm (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=21, Completed, Sponsor: University Hospital, Ghent
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jan 2015 Recruiting --> Completed | N=100 --> 21 | Trial primary completion date: Dec 2015 --> Mar 2016
- Odomzo (sonidegib) / Sun Pharma
Phase classification, Enrollment change: Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer (clinicaltrials.gov) - Mar 11, 2016
P1, N=15, Recruiting, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed | N=100 --> 21 | Trial primary completion date: Dec 2015 --> Mar 2016 Phase classification: P1/2 --> P1 | N=59 --> 15
- || Talzenna (talazoparib) / Pfizer
Enrollment change, Trial primary completion date, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Mar 10, 2016
P1, N=74, Active, not recruiting, Sponsor: Medivation, Inc.
Phase classification: P1/2 --> P1 | N=59 --> 15 N=113 --> 74 | Trial primary completion date: Jan 2016 --> Mar 2015
- | New P4 trial: Comparison Between D&C and Hysteroscopy in Management of AUB in Perimenopausal Women (clinicaltrials.gov) - Mar 10, 2016
P4, N=100, Recruiting, Sponsor: Mohamed Sayed Abdelhafez
- Biomarker, New trial: Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: Shaare Zedek Medical Center
- Trial primary completion date: Impact on Ovarian Reserve of Diode Laser vs Bipolar Coagulation of Endometriomas (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=50, Recruiting, Sponsor: University of Cagliari
N=113 --> 74 | Trial primary completion date: Jan 2016 --> Mar 2015 Trial primary completion date: Jan 2016 --> Jan 2017
- Avastin (bevacizumab) / Roche
Trial primary completion date: Bevacizumab and Carboplatin for Patients With Ovarian Cancer (clinicaltrials.gov) - Mar 9, 2016
P2, N=30, Active, not recruiting, Sponsor: Vejle Hospital
Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Feb 2016 --> Aug 2015
- Trial completion: Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=210, Completed, Sponsor: Herlev Hospital
Trial primary completion date: Feb 2016 --> Aug 2015 Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=35, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 35 | Trial primary completion date: Apr 2016 --> Jul 2015
- | Trial completion: Utilization of HIV Clinical Services in Rural India (clinicaltrials.gov) - Mar 9, 2016
P3, N=1300, Completed, Sponsor: Institute of Health Management, Pachod, India
Active, not recruiting --> Completed | N=60 --> 35 | Trial primary completion date: Apr 2016 --> Jul 2015 Enrolling by invitation --> Completed
- New trial: Furocyst - Poly Cystic Ovary Syndrome Study (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=120, Recruiting, Sponsor: Chemical Resources
- New trial: Acupuncture for Vulvodynia: A Pre-pilot Study (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=6, Recruiting, Sponsor: University of Illinois at Chicago
- Enrollment change, Trial withdrawal: Closed Vitrification of Oocytes (clinicaltrials.gov) - Mar 9, 2016
P=N/A, N=0, Withdrawn, Sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Enrolling by invitation --> Completed N=604 --> 0 | Recruiting --> Withdrawn
- |||| HSV vaccine (GEN-003) / Genocea, Shionogi
Trial completion: Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - Mar 8, 2016
P2, N=310, Completed, Sponsor: Genocea Biosciences, Inc.
N=604 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- Enrollment closed: PVD/tDCS: Efficacy of Transcranial Direct-Current Stimulation (tDCS) for Provoked Vestibulodynia : a Triple Blind Randomized Controlled Trial (clinicaltrials.gov) - Mar 8, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: Universit
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=10, Completed, Sponsor: Medtronic - MITG
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Victoza (liraglutide) / Novo Nordisk
Trial completion, Trial primary completion date: LIPT - Liraglutide in Polycystic Ovary Syndrome (clinicaltrials.gov) - Mar 5, 2016
P4, N=72, Completed, Sponsor: Jens Faber
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Dec 2015
- Enrollment open: Fermented Wheat Germ Extract in Women With Ovarian Cancer (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=20, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- Enrollment open, Enrollment change, Trial primary completion date: Hula, a Physical Activity Intervention for Female-Cancer Survivors (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=100, Recruiting, Sponsor: University of Hawaii
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | N=20 --> 100 | Trial primary completion date: Apr 2015 --> Dec 2017
- | Lovaxin C (axalimogene filolisbac) / Ayala Pharma
Enrollment open: Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer (clinicaltrials.gov) - Mar 4, 2016
P1/2, N=25, Recruiting, Sponsor: Advaxis, Inc.
Active, not recruiting --> Recruiting | N=20 --> 100 | Trial primary completion date: Apr 2015 --> Dec 2017 Active, not recruiting --> Recruiting
- New trial, Video: Video Colposcopy in Women With Dysplasia (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=240, Not yet recruiting, Sponsor: Zydolab - Institute of Cytology and Immune Cytochemistry
- |||| Enrollment open: A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy (clinicaltrials.gov) - Mar 4, 2016
P2, N=200, Recruiting, Sponsor: Warner Chilcott
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- New trial: Sterile Water Injections For Pain Relief İn Labor (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=168, Completed, Sponsor: University of Beykent
- New trial, Biopsy: The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=128, Recruiting, Sponsor: Women and Infants Hospital of Rhode Island
- Enrollment open: ISOTOVE: Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=20, Recruiting, Sponsor: Centre Jean Perrin
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- navitoclax (ABT 263) / AbbVie
Enrollment open: MONAVI-1: A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer (clinicaltrials.gov) - Mar 4, 2016
P2, N=46, Recruiting, Sponsor: Centre Francois Baclesse
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- New trial, Cytology: DEPIST: Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care (clinicaltrials.gov) - Mar 4, 2016
P=N/A, N=667, Completed, Sponsor: University Hospital, Geneva
- Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: SyphPoc: Syph-Check Syphilis Antibody Point of Care (POC) Test (clinicaltrials.gov) - Mar 3, 2016
P=N/A, N=400, Terminated, Sponsor: Healthcare Providers Direct, Inc.
Active, not recruiting --> Recruiting N=600 --> 400 | Initiation date: Oct 2008 --> Mar 2009 | Not yet recruiting --> Terminated | Trial primary completion date: Feb 2009 --> Feb 2010; insufficient patient populations
- New trial: FemCure: Transmission of Genital and Extra-genital Chlamydia Trachomatis Infections in Women (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=400, Not yet recruiting, Sponsor: Maastricht University Medical Center
- New trial: OB-PCO: The Effect of Obesity on Endometrium in PCOS (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=100, Completed, Sponsor: Assiut University
- ||| Enrollment open, Trial initiation date: FILM: A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=150, Recruiting, Sponsor: Novadaq Technologies Inc.
N=600 --> 400 | Initiation date: Oct 2008 --> Mar 2009 | Not yet recruiting --> Terminated | Trial primary completion date: Feb 2009 --> Feb 2010; insufficient patient populations Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Dec 2015
- Disalcid (salsalate) / Bausch Health
Trial primary completion date: ELI-ROAS: Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Feb 29, 2016
P=N/A, N=60, Recruiting, Sponsor: Indiana University
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Dec 2016
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P2, N=45, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion: Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer (clinicaltrials.gov) - Feb 27, 2016
P2, N=21, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed